In case you missed SenzaGen’s Scientific Session at this year’s SOT, here is a new opportunity! Together with guest speakers from ExxonMobil Biomedical Sciences Inc. and Research Institute for Fragrance Materials, Inc. (RIFM), SenzaGen’s Andy Forreryd, PhD will present the latest GARD® data on quantitative risk assessment and regulatory testing of skin sensitizers, and the […]
Join this free webinar to learn how you can avoid animal testing and accelerate time to market by using results from in vitro testing for the endpoints of cytotoxicity, skin irritation and skin sensitization in your biological evaluation for CE-marking of your medical device in line with the EU Medical Device Regulation 2017/745, the MDR. […]
Join this free webinar where Ron Brown, toxicologist and former FDA risk assessor, will outline the need for a new and more agile approach for the biological safety assessment of medical devices. This presentation will identify the limitations associated with the current approach, which largely relies on animal-based tests that may have questionable clinical relevance. […]
We invite you to participate in our webinar where new cutting edge GARD results will be explained by the experts at SenzaGen and our partners. In case you missed SenzaGen’s Scientific Posters and Oral Presentations at this year’s WC12 in Niagara Falls or Eurotox in Ljubljana, we are pleased to offer you a new opportunity […]
Join our upcoming free webinar to explore the effective utilization of in vitro methods for safety assessment of materials during product development of Medical Devices. We will discuss recent advancements in in vitro methods for assessing the endpoints of skin irritation and skin sensitization. Learn how to integrate these assessments into your product development process […]
Join our upcoming webinar to explore the recent advancement in GARD® for Skin Sensitization assessment, with a specific focus on substances that fall outside the applicability domains of the conventional in vitro assays in the OECD Test Guidelines. Our skin sensitization experts will address challenges posed by various Difficult-to-Test substances, discussing the applicability domain of […]
Spotlight on Applicability Domain, Quantitative Potency Assessment and Medical Devices In case you missed SenzaGen’s poster presentations and scientific session at this year’s SOT, we are pleased to offer you a new opportunity to participate on April 23, 2024! In this webinar Dr Andy Forreryd, SenzaGen's in vitro toxicology expert, will summarize the latest GARD data from industry collaborations: […]
Spotlight on in vitro quantitative assessment of skin sensitizing potency. Join our upcoming webinar to explore the recent advancement in GARD® for quantitative assessment of skin sensitizing potency. This session will present a meta-analysis of GARD® data covering over 200 chemicals, including three blinded datasets generated in collaboration with industry partners. These data will demonstrate […]
Spotlight on Point-of-Departure, Challenging Substances, and Active Ingredients We invite you to join our upcoming webinar, where industry leaders from Lundbeck, Unilever, and Cargill, along with experts from SenzaGen will explain the latest advancements in skin sensitization testing. Join us as we explore the latest data from our GARD® platform on skin sensitization and gain […]
Join us for a special re-run of our popular GARD® webinar to explore the recent advancement in Skin Sensitization testing, focusing on substances that fall outside the applicability domains of the conventional in vitro assays in the OECD Test Guidelines. Our skin sensitization experts will address challenges posed by various "Difficult-to-Test" substances, discussing the applicability […]
